UL42 is the DNA polymerase accessory protein of herpes simplex virus type 1.
| Institute |
|---|
| Cancer Research UK, London Research Institute: Clare Hall Laboratories |
| Cat. #: | 151033 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Microbiology |
| Application: | FACS ; IHC ; IF ; IP ; WB |
| Target: | Herpes Simplex Virus protein UL42 (HSV-UL42) |
| Reactivity: | Virus |
| Clone: | 13C9 |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | UL42 is the DNA polymerase accessory protein of herpes simplex virus type 1. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | Baculovirus-expressed HSV DNA polymerase (POL) and POL/UL42 complex. |
| Myeloma used: | Sp2/0-Ag14 |
| Target background: | UL42 is the DNA polymerase accessory protein of herpes simplex virus type 1. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Iwahori et al. 2007. J Virol. 81(18):9653-64. PMID: 17609267. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151030 | Anti-Progesterone [11P14] |
Key Info
Anti-Progesterone [11P14]
|
View Tool | |||||||||||||||||||
| 151015 | Anti-CyclinA [E70.1] |
Key Info
Anti-CyclinA [E70.1]
|
View Tool | |||||||||||||||||||
| 151023 | Anti-IL12 [1-1D5] |
Key Info
Anti-IL12 [1-1D5]
|
View Tool | |||||||||||||||||||
| 151028 | Anti-Cytochrome P450 2C2, 2B1/2 [h7] |
Key Info
Anti-Cytochrome P450 2C2, 2B1/2 [h7]
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.